InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (87)	4/5/2001 8:39:27 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) of 508

Thanks Nigel - you beat me to it. The most interesting thing in the announcement is, "initiated a Phase I clinical trial there evaluating the safety of inhaled ACTIMMUNE®". This is the first mention of testing 'inhaled" Actimmune that I have heard. At the American Academy of Chest Physicians meeting in Marvin Schwartz argued for inhaled delivery. This would make sense in lung diseases like IPF and TB by delivering the drug to the disease site. This is also new - "InterMune also announced that it plans to develop ACTIMMUNE® for the treatment of liver fibrosis (cirrhosis) associated with hepatitis C infection." The anti-fibrotic properties of Actimmune are not new but this is the first mention I have heard of using it to treat HCV. Hope it works. This is great news IMO. ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next